On March 14, 2025,  Azurity Pharmaceuticals announced the successful completion of its acquisition of Covis from existing investors. With this acquisition, Covis is now a wholly owned subsidiary of Azurity. Wilson Sonsini Goodrich & Rosati advised Azurity on litigation matters related to the transaction.

The acquisition expands Azurity's therapeutic portfolio to include 10 complex dosage forms and nine key therapeutic areas, such as cardiovascular and oncology, while increasing its global presence to over 50 countries and employing over 800 staff worldwide.

The Wilson Sonsini team that advised Azurity on litigation matters related to the acquisition includes Wendy Devine, Jeff Bank, Brad Tennis, Emily Shingle, Jessica Lonergan, Dan Orr, and Christine Au-Yeung.

For more information, please see Azurity's news release. Additional coverage can be found on The Pharma Letter.